Drug Profile
Research programme: inflammatory disease therapeutics - Array BioPharma/Celgene Corporation
Latest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Celgene Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA